Home › NCT07674680

Beta3-adrenergic Receptors and Cardiovascular Function in Aging Women

Who can join

Ages 18 to 70 · Women · Healthy volunteers welcome

Inclusion Criteria:

* Healthy women,
* Assigned female at birth,
* 18-70 years of age,
* Body mass index \<18 or ≥30 kg/m2,

Exclusion Criteria:

* Assigned male at birth,
* Pregnancy,
* Breastfeeding,
* History of hormone replacement therapy, chemical menopause, or oophor-ectomy
* Polycystic ovarian syndrome or Primary ovarian insufficiency,
* Current smoking/Nicotine use,
* Blood pressure ≥140/90 mmHg,
* Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,
* Nerve/neurologic disease,
* Cardiovascular, hepatic, renal, respiratory disease,
* Hypersensitivity to nitroglycerin,
* Diabetes,
* Communication barriers,

About the study

To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.

What is being tested

• Placebo (drug)
• Gemtesa (drug)

Sponsor: University of Missouri-Columbia · Participants: 60 · Started: Jul 31, 2026

Contact the study team

• Jacqueline Limberg Associate Professor · Phone: 1-573-882-2544

Official record on ClinicalTrials.gov — NCT07674680

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.